Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envolizumab + SOX as neoadjuvant therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400087908Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Peking Union Medical College Hospital. Primary endpoint: rate of pathologic complete response. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400087908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087908.